Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Preclinical Toxicological Evaluation of 7-Methoxy-3-Phenyl-4H-Chromen-4-one: Acute and Sub-acute Oral Toxicity with Histopathological Correlation.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·2026

Same author

Reirradiation for recurrent head and neck squamous cell carcinoma: international expert consensus recommendations endorsed by the Reirradiation Collaborative Group, the European Society for Radiotherapy and Oncology Reirradiation Focus Group, and the American Society for Radiation Oncology.

The Lancet. Oncology·2026

Same author

Stage-Specific Molecular Cargo of Schwann Cell-Derived Extracellular Vesicles is Associated With Peripheral Nerve Repair.

Journal of extracellular biology·2026

Same author

From sugar to flames: the detrimental role of pyroptosis in diabetes-associated bone loss.

Molecular biology reports·2026

Same author

Alogliptin-metformin synergy ameliorates diabetes-associated bone loss via modulation of DPP-4 activity and OPG/RANKL signaling.

3 Biotech·2026

Same author

Beyond Hyperglycaemia in Diabetic Bone Disease: Refining Experimental Models of Diabetes-Induced Osteopathy.

Diabetes/metabolism research and reviews·2026

Same journal

Upper gastrointestinal bleeding due to gastric stromal tumour: a case report.

Cases journal·2010

Same journal

Interstitial lung disease associated to erlotinib treatment: a case report.

Cases journal·2010

Same journal

Repair of a defect following the removal of an impacted maxillary canine by orthodontic tooth movement: a case report.

Cases journal·2010

Same journal

Dihydrotachysterol intoxication treated with pamidronate: a case report.

Cases journal·2010

Same journal

Posttraumatic proliferating trichilemmal tumour on the frontal region of the scalp: a case report.

Cases journal·2010

Same journal

Acute Subarachnoid Hemorrhage and Cardiac Abnormalities: Takotsubo Cardiomyopathy or Neurogenic Stunned Myocardium? a case report.

Cases journal·2010

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

Standardized cannabis in multiple sclerosis: a case report.

Paul Hornby¹, Manju Sharma

¹Department of Medical Cannabis Research, The Green Cross Society of BC, 2127, Kingsway, Vancouver, B.C., V5N 2T4, Canada.

|January 16, 2010

Summary

This summary is machine-generated.

This study found that a daily intake of 500 mg of Tetrahydrocannabinol (THC) from cannabis improved quality of life for a patient with severe multiple sclerosis over one year.

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

Related Experiment Videos

Last Updated: Jun 17, 2026

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

Area of Science:

Neurology
Pharmacology

Background:

Multiple sclerosis (MS) is a progressive, debilitating neurological disease.
Managing severe symptoms, including pain, is crucial for patient quality of life.

Purpose of the Study:

To evaluate the efficacy of standardized cannabis in managing severe progressive multiple sclerosis symptoms.
To determine the required dosage of Tetrahydrocannabinol (THC) for improving quality of life in MS patients.

Main Methods:

A single patient with severe progressive multiple sclerosis was monitored for one year.
Quantifiable amounts of standardized cannabis were administered.
Daily pain charts and condition records were maintained.

Main Results:

An average daily intake of 500 mg of Tetrahydrocannabinol (THC) was required.
This dosage achieved a desired quality of life for the patient.

Conclusions:

Standardized cannabis, specifically Tetrahydrocannabinol (THC), may be a viable option for managing severe progressive multiple sclerosis.
Further research is warranted to confirm these findings in a larger cohort.